SECT-B Stock Analysis: Sectra (publ) | ST
Medical Devices | ST, Sweden | Market Cap: 55.912m SEK | 12M Return: 2.5% | SE0022419784 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 50.4M
EPS Trend: 78.9%
Qual. Beats: 0
Rev. Trend: 97.7%
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
The Imaging IT Solutions segment is the core business, providing systems for capturing, archiving, presenting, and sharing medical images and patient information, along with maintenance, system monitoring, and consulting. This segment operates in the healthcare IT sub-sector focused on diagnostic imaging workflows (commonly encompassing radiology and pathology PACS and related enterprise imaging platforms), which is structurally tied to hospital capital expenditure cycles and regulatory requirements around patient data handling.
The Secure Communications segment supplies encrypted voice and data communication solutions, security and threat analyses, and system monitoring for industrial control systems, serving government and critical infrastructure clients. The smaller Business Innovation unit develops niche products such as orthopedic surgery planning software, medical education tools, and IT support for precision cancer diagnostics. A residual Other Operations segment handles property management activities.
- Hospital imaging IT orders drive recurring revenue growth
- Secure Communications benefits from rising European defense spending
- Competition from Philips and GE pressures imaging market share
| Net Income: 619.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.19 > 0.02 and ΔFCF/TA -7.70 > 1.0 |
| NWC/Revenue: 40.35% < 20% (prev 40.70%; Δ -0.35% < -1%) |
| CFO/TA 0.22 > 3% & CFO 981.9m > Net Income 619.0m |
| Net Debt (-1.62b) to EBITDA (843.1m): -1.93 < 3 |
| Current Ratio: 1.75 > 1.5 & < 3 |
| Outstanding Shares: last quarter (182.0m) vs 12m ago -5.52% < -2% |
| Gross Margin: 24.72% > 18% (prev 89.05%; Δ -64.32% > 0.5%) |
| Asset Turnover: 90.62% > 50% (prev 87.33%; Δ 3.28% > 0%) |
| Interest Coverage Ratio: 102.1 > 6 (EBIT TTM 767.6m / Interest Expense TTM 7.52m) |
| A: 0.34 (Total Current Assets 3.51b - Total Current Liabilities 2.00b) / Total Assets 4.49b |
| B: 0.40 (Retained Earnings 1.81b / Total Assets 4.49b) |
| C: 0.19 (EBIT TTM 767.6m / Avg Total Assets 4.13b) |
| D: 1.07 (Book Value of Equity 2.32b / Total Liabilities 2.17b) |
| Altman-Z'' = 5.89 = AAA |
| DSRI: 3.0 (Receivables 1.46b/419.7m, Revenue 3.74b/3.28b) |
| GMI: 3.60 (GM 89.05% / 24.72%) |
| AQI: 0.84 (AQ_t 0.12 / AQ_t-1 0.15) |
| SGI: 1.14 (Revenue 3.74b / 3.28b) |
| TATA: -0.08 (NI 619.0m - CFO 981.9m) / TA 4.49b) |
| Beneish M = 0.97 (Cap -4..+1) = D |
As of October 10, 2026, the stock is trading at SEK 310.20 with a total of 147,473 shares traded. Over the past week, the price has changed by +6.89%, over one month by +8.92%, over three months by +9.86% and over the past year by +2.52%.
Current recommended Stop Loss: 294.30 (which is 5.1% or 1.7 ATR below the current price).
Sectra (publ) has no consensus analysts rating.
P/E Trailing = 90.1242
P/E Forward = 71.4286
P/S = 14.9334
P/B = 23.2864
Revenue TTM = 3.74b SEK
EBIT TTM = 767.6m SEK
EBITDA TTM = 843.1m SEK
Long Term Debt = 95.9m SEK (estimated: total debt 127.6m - short term 31.8m)
Short Term Debt = 31.8m SEK (from shortTermDebt, last quarter)
Debt = 127.6m SEK (from shortLongTermDebtTotal, last quarter) (leases 127.6m already included)
Net Debt = -1.62b SEK (calculated: Debt 127.6m - CCE 1.75b)
Enterprise Value = 54.3b SEK (55.9b + Debt 127.6m - CCE 1.75b)
Interest Coverage Ratio = 102.1 (Ebit TTM 767.6m / Interest Expense TTM 7.52m)
EV/FCF = 63.95x (Enterprise Value 54.3b / FCF TTM 848.9m)
FCF Yield = 1.56% (FCF TTM 848.9m / Enterprise Value 54.3b)
FCF Margin = 22.70% (FCF TTM 848.9m / Revenue TTM 3.74b)
Net Margin = 16.56% (Net Income TTM 619.0m / Revenue TTM 3.74b)
Gross Margin = 24.72% ((Revenue TTM 3.74b - Cost of Revenue TTM 2.81b) / Revenue TTM)
Gross Margin QoQ = 34.78% (prev 20.50%)
Tobins Q-Ratio = 12.08 (Enterprise Value 54.3b / Total Assets 4.49b)
Interest Expense / Debt = 5.89% (Interest Expense 7.52m / Debt 127.6m)
Taxrate = 22.44% (179.0m / 797.9m)
NOPAT = 595.4m (EBIT 767.6m * (1 - 22.44%))
Current Ratio = 1.75 (Total Current Assets 3.51b / Total Current Liabilities 2.00b)
Debt / Equity = 0.05 (Debt 127.6m / totalStockholderEquity, last quarter 2.32b)
Debt / EBITDA = -1.93 (Net Debt -1.62b / EBITDA 843.1m)
Debt / FCF = -1.91 (Net Debt -1.62b / FCF TTM 848.9m)
Total Stockholder Equity = 2.05b (last 4 quarters mean from totalStockholderEquity)
RoA = 15.00% (Net Income 619.0m / Total Assets 4.49b)
RoE = 30.26% (Net Income TTM 619.0m / Total Stockholder Equity 2.05b)
RoCE = 35.85% (EBIT 767.6m / Capital Employed (Equity 2.05b + L.T.Debt 95.9m))
RoIC = 25.46% (NOPAT 595.4m / Invested Capital 2.34b)
WACC = 6.46% (E(55.9b)/V(56.0b) * Re(6.46%) + D(127.6m)/V(56.0b) * Rd(5.89%) * (1-Tc(0.22)))
Discount Rate = 6.46% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -52.22 | Cagr: -2.49%
[DCF] Terminal Value 73.10% ; FCFF base≈909.0m ; Y1≈797.1m ; Y5≈644.0m
[DCF] Fair Price = 66.62 (EV 10.3b - Net Debt -1.62b = Equity 12.0b / Shares 179.6m; r=8.35% [WACC [floored]]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: 78.86 | EPS CAGR: 16.68% | SUE: 0.36 | # QB: 0
Revenue Correlation: 97.71 | Revenue CAGR: 11.00% | SUE: 0.14 | # QB: 0
EPS current Quarter (2026-10-31): EPS=0.85 | Chg30d=N/A | Revisions=+0% | Analysts=1
EPS next Quarter (2027-01-31): EPS=0.91 | Chg30d=N/A | Revisions=+0% | Analysts=1
EPS current Year (2027-04-30): EPS=3.83 | Chg30d=+5.23% | Revisions=-25% | GrowthEPS=+30.6% | GrowthRev=+17.6%
EPS next Year (2028-04-30): EPS=4.95 | Chg30d=+3.23% | Revisions=+40% | GrowthEPS=+29.4% | GrowthRev=+16.2%
[Analyst] Revisions Ratio: +17% (up=2, down=1)